Stockscreener 앱 받기
0.91
5.78%
0.0497
시간 외 거래:
.95
0.04
+4.40%
전일 마감가:
$0.8603
열려 있는:
$0.879
하루 거래량:
614.86K
Relative Volume:
1.18
시가총액:
$74.98M
수익:
$38.70M
순이익/손실:
$-117.88M
주가수익비율:
-0.3346
EPS:
-2.72
순현금흐름:
$-92.84M
1주 성능:
-5.68%
1개월 성능:
-5.90%
6개월 성능:
-33.09%
1년 성능:
-37.67%
1일 변동 폭
$0.86
$0.9171
1주일 범위
$0.81
$0.98
52주 변동 폭
$0.81
$3.77
Adicet Bio Inc Stock (ACET) Company Profile
명칭
Adicet Bio Inc
전화
617-482-2333
주소
131 DARTMOUTH STREET, BOSTON
ACET을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.91 | 74.98M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-30 | 재개 | Guggenheim | Buy |
| 2024-09-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-06-27 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-03-31 | 개시 | SMBC Nikko | Outperform |
| 2022-03-08 | 개시 | Truist | Buy |
| 2022-03-04 | 개시 | Jefferies | Buy |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2021-04-23 | 개시 | H.C. Wainwright | Buy |
| 2021-04-14 | 개시 | Canaccord Genuity | Buy |
| 2021-04-08 | 개시 | Guggenheim | Buy |
| 2020-11-04 | 개시 | B. Riley Securities | Buy |
| 2020-10-27 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-16 | 개시 | Wedbush | Outperform |
모두보기
Adicet Bio Inc 주식(ACET)의 최신 뉴스
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - Yahoo! Voices
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
Adicet Bio's (ACET) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Adicet Bio begins trial for kidney cancer therapy - Investing.com
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace
ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - BioSpace
Adicet Bio Names Dr. Julia Maltzman As Chief Medical Officer - Contract Pharma
Adicet Bio names new Chief Medical Officer - Investing.com
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - MarketBeat
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1% - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces CAR-T challenges - Investing.com
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Rises By 6.1% - MarketBeat
Adicet Bio Awards New Employee Stock Options at $1.13 Per Share in Inducement Grant | ACET Stock News - StockTitan
Adicet Bio clears debt with Banc of California By Investing.com - Investing.com South Africa
Adicet Bio clears debt with Banc of California - Investing.com India
Adicet Bio Clears Debts with Banc of California - TipRanks
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Has $56,000 Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio, Inc. Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Marketscreener.com
Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq
Adicet Bio begins trial for innovative cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks
Adicet Bio begins trial for innovative cancer therapy - Investing.com
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
Adicet Bio begins lupus nephritis trial, eyes other diseases By Investing.com - Investing.com Canada
Adicet Bio's (ACET) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Adicet Bio begins lupus nephritis trial, eyes other diseases - Investing.com
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Adicet Bio Launches Phase 1 Trial for Lupus Drug with FDA Fast Track Status - StockTitan
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
Adicet Bio's ADI-001 Shows Breakthrough CAR T Cell Results in Autoimmune Treatment Study - StockTitan
Adicet Bio amends loan terms with PacWest Bank By Investing.com - Investing.com Nigeria
RA Capital Management, L.P. Expands Stake in Adicet Bio Inc - GuruFocus.com
ACET stock touches 52-week low at $1.04 amid market challenges - Investing.com
Adicet Bio To Present At Guggenheim Securities Healthcare Innovation Conference; Webcast At 3:00 PM - Nasdaq
FY2024 EPS Estimates for Adicet Bio Lowered by HC Wainwright - MarketBeat
HC Wainwright Decreases Earnings Estimates for Adicet Bio - Defense World
Wedbush Reiterates “Outperform” Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio (NASDAQ:ACET) Announces Earnings Results, Hits Estimates - MarketBeat
Adicet Bio Expands Trial Portfolio, Secures FDA Fast Track Status Despite $30.5M Loss | ACET Stock News - StockTitan
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences - Business Wire
Adicet Bio Inc (ACET) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adicet Bio Inc 주식 (ACET) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jan 25 '24 |
Buy |
2.40 |
3,125,000 |
7,500,000 |
7,526,359 |
| GORDON CARL L | Director |
Jan 25 '24 |
Buy |
2.40 |
3,125,000 |
7,500,000 |
7,526,359 |
2.88%
2.65%
자본화:
|
볼륨(24시간):